Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.
Mahlich, Jörg; Kamae, Isao; Sruamsiri, Rosarin.
Expert Rev Pharmacoecon Outcomes Res
; 18(3): 339-348, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29039214
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.
Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation.
Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.
Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis.
Costs and disease activity in early rheumatoid arthritis in 1996-2000 and 2006-2011, improved outcome and shift in distribution of costs: a two-year follow-up.
Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
Treat-to-target: not as simple as it appears.
Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review.